BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, September 23, 2023
Home » Blogs » BioWorld MedTech Perspectives » Combination diagnostics lead discussion for Cleveland Clinic's Medical Innovation Summit

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech / Diagnostics

Combination diagnostics lead discussion for Cleveland Clinic's Medical Innovation Summit

Nov. 6, 2014
By Omar Ford
No Comments
Docgraham

IMG_0303So what were the major talking points coming out of Cleveland Clinic's Medical Innovation Summit? It certainly wasn't a discussion on the lack of venture capital dollars available for med-tech start-ups - a topic that used to dominate conversations a few years back. Nor was it about the Affordable Care Act.

No, the major talk at this year's Medical Innovation Summit, which was held last week, revolved around companion diagnostics. Look for new and exciting pharmaceuticals to be married to diagnostic tests for the foreseeable future. It seems in nearly every other panel something about combination diagnostics was mentioned. One pharma company executive went so far as to say that his company doesn't even start development of a new pharma product without thinking of how a diagnostic could work along with it.

And let's face it, with healthcare in full migration to a results-based only model, this is going to become the new norm. In a discussion with Myriad Genetics' President Mark Capone, he noted that "five years ago, you would have generally seen pharmaceutical companies try their best to develop a drug without a diagnostic. I think we've transitioned to the point where the recognition is that without a diagnostic, companies might have difficulty getting approval."

While this could be a tremendous boon for many diagnostic companies - or create a headache when discussing royalties - I wonder if pharmaceutical companies will go on a sizeable acquisition spree for diagnostics firms in the future.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Sept. 22, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for September 22, 2023.
  • Hands holding torn contract

    Quite a fix: Orthofix sacks three top execs

    BioWorld MedTech
    Orthofix Medical Inc. terminated its CEO, chief financial officer and chief legal officer in a move that plunged the stock from $18.63 at Monday’s close to $13.01...
  • Illustration of Alzheimer’s in the brain.

    Study identifies cause of death for Alzheimer’s neurons

    BioWorld
    By creating a new mouse model of Alzheimer’s disease that better recapitulated how the disease plays out in humans, investigators at KU Leuven have gained new...
  • New NLRP3 inflammasome inhibitors named in PTC Therapeutics patent

    BioWorld Science
    PTC Therapeutics Inc. has patented new NLRP3 inflammasome inhibitors reported to be useful...
BioFuture ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing